Breaking News, Financial News

Financial Report: Johnson & Johnson 4Q

Worldwide Pharmaceutical sales were $22.5 billion for the year (-8%), while Worldwide Medical Devices and Diagnostics sales were $23.6 billion for year (+2%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 4Q 4Q Revenues: $16.6 billion (+9%) 4Q Earnings: $2.2 billion (-19%) FY Revenues: $61.9 billion (-3%) FY Earnings: $12.3 billion (-5%) Comments: Worldwide Pharmaceutical sales were $22.5 billion for the year (-8%), while Worldwide Medical Devices and Diagnostics sales were $23.6 billion for year (+2%). Products with operational growth for the year included: Remicade, Prezista, Velcade, Risperdal, Consta. Sales of Topamax and Risperdal were negatively impacted...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters